NCT01614756View on ClinicalTrials.gov

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy Subjects and Atopic Dermatitis Subjects
Interventions
BIOLOGICAL

BMS-981164

BIOLOGICAL

Placebo matching with BMS-981164

Trial Locations (4)

M15 6SH

Local Institution, Manchester

NE1 4LP

Local Institution, Newcastle upon Tyne

M6 8HD

Local Institution, Manchester

NG11 6JS

Local Institution, Nottingham

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01614756 - A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis | Biotech Hunter | Biotech Hunter